24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Diabetes
Resources
Basic InformationLatest News
Next-Gen Artificial Pancreas Boosts Blood Sugar ControlHurricanes Raise Death Risk for Older Diabetics, Even Years LaterYou've Lost the Weight -- Now Keep It Off to Keep Diabetes at BayCould a Pill Replace Insulin Shots?High-Fiber Diet Tied to Lower Heart Risk in Diabetes PatientsJust a Little Weight Loss Can Put Diabetes Into RemissionAffordable Care Act Insured Millions of Uninsured DiabeticsOlder Diabetics May Be Getting Too Much InsulinIt Takes Less Weight to Trigger Diabetes in Minorities Than WhitesFDA OKs New Pill for Type 2 DiabetesAHA News: These Diets Helped Women With Diabetes Cut Heart Attack, Stroke RiskKeeping Blood Sugar Steady Helps You Live Longer With DiabetesAre Shorter Folks at Higher Risk for Type 2 Diabetes?Diabetes Control Has Stalled Across U.S.Fish Oil Not a Magic Pill Against DiabetesAsian Study Finds Diabetes, Heart Failure a Dangerous DuoCaring Doctors Can Be Life-Changing for Diabetic PatientsKeto Diet May Help Control Type 2 DiabetesHealth Tip: Living With HypoglycemiaHealth Tip: Understanding PrediabetesFDA Approves First Needle-Free 'Rescue' Drug for Low Blood Sugar EpisodesDiabetes Raises Heart Failure Risk More in Women Than MenCan You Live Well With Type 1 Diabetes for 81 Years? Just Ask Don RayEasing Depression Can Bring Longer Life to People With DiabetesMedtronic Recalls Some Insulin Pumps as FDA Warns They Could Be HackedFDA Approves Victoza Injection for Children 10 Years and OlderCommon Infant Vaccine May Also Shield Kids From Type 1 DiabetesType 1 Diabetes Might Affect Young Kids' Brain DevelopmentDrug May Help Delay Onset of Type 1 DiabetesVitamin D Supplements Don't Prevent Type 2 Diabetes: StudyWhat and How You Eat Affects Your Odds for Type 2 DiabetesAHA News: Diabetes and Heart Failure Are Linked; Treatment Should Be TooMidlife Diabetes Can Really Raise Your Odds for Stroke Years LaterTight Diabetes Control Alone May Not Benefit the Heart Long-TermOpen Communication Helps Teens Manage Type 1 DiabetesNew Gene Variants for Type 2 Diabetes FoundPost-Hospital Low Blood Sugar a Danger to DiabeticsAHA News: Why Are Women With Diabetes at Greater Risk for Poor Heart Health?Newer Diabetes Drugs Linked to 'Flesh-Eating' Genital InfectionAHA News: Study Backs Lower Blood Pressure Target for People With DiabetesNewer Diabetes Drug Shows Promise in Kids, TeensNo 'One-Size-Fits-All' Diet for Diabetics, Expert Panel SaysMicrobes in Diabetic Foot Ulcers May Help Predict Treatment SuccessCommon Diabetes Drug May Also Shield Kidneys, HeartThe Earlier You Develop Type 2 Diabetes, the Greater Your Heart RisksHigh Insulin Costs Come Under Fire on Capitol HillType 1 Diabetics Often Unaware of Low Blood Sugar EpisodesCommon Diabetes Test May Often Miss the MarkHealth Tip: Reading Food Labels for DiabeticsWhich Type of Exercise Might Lower Your Diabetes Risk?
Links
Related Topics

Medical Disorders

Study Eases Concern That Common Diabetes Med Might Harm Bones

HealthDay News
by By Serena Gordon
HealthDay Reporter
Updated: Jan 3rd 2019

new article illustration

THURSDAY, Jan. 3, 2019 (HealthDay News) -- If you have type 2 diabetes and you're taking canagliflozin to help control your blood sugar, a new study has some good news for you: The drug doesn't appear to raise the risk of bone fractures.

Previously, research had suggested this might be the case.

"We were interested in doing this study because there was one randomized trial that said there was an increased risk of bone fractures and another that said there wasn't. So, we conducted a real-world study with almost 200,000 people with type 2 diabetes," said study author Dr. Michael Fralick.

"I hope these findings are reassuring to patients and physicians because these are blockbuster medications for type 2 diabetes. This class of medicines can improve blood sugar levels and help reduce heart disease risk," he said. Fralick is from the division of pharmacoepidemiology and pharmacoeconomics at Brigham and Women's Hospital in Boston, and a general internist at the University of Toronto.

Canagliflozin (Invokana, Invokamet) is one drug in a class of medications called SGLT-2 inhibitors. Other drugs in this class include dapagliflozin (Farxiga) and empagliflozin (Jardiance).

These drugs cause the kidneys to remove excess sugar from the blood and excrete it through urine, which lowers blood sugar levels, according to the U.S. Food and Drug Administration. This class of drugs has been linked to a number of complications, including kidney injury and serious genital infections.

Fralick said one way these drugs could potentially increase fracture risk is by lowering bone mineral density.

Dr. William Leslie, author of an editorial accompanying the study, suggested that dehydration may be another way these drugs might be linked to fracture risk. Leslie is a professor of medicine and radiology at the University of Manitoba in Canada.

For the new report, Fralick and his team reviewed data from two U.S. commercial health care databases. They found information on about 200,000 people with type 2 diabetes who were just starting to take one of two different type 2 diabetes medications -- canagliflozin or a medication in a class of drugs called GLP-1 agonists, which includes Victoza, Trulicity and Byetta. These drugs haven't been linked to an increased risk of fractures.

The researchers looked for fractures in the upper and lower arms, as well as the hips and pelvis.

In the end, the study team compared approximately 80,000 people on canagliflozin to about 80,000 treated with GLP-1 agonists. The patients' average age was 55, and about 48 percent were female.

The study showed a similar risk of fractures in these low-risk, middle-aged populations.

Both Fralick and Leslie said the jury is still out for people who are at a higher risk of fractures, such as elderly people.

This study is "a relatively low-risk population. But, it begs the question, what about higher-risk populations? We need additional safety data," Leslie said.

The U.S. Food and Drug Administration currently requires canagliflozin labels to carry a warning about the potential fracture risk, and Fralick said it may be too soon to change the labeling, particularly for people at high risk. Both experts said more research is needed.

In the meantime, if you're concerned about taking canagliflozin, Fralick recommended having a conversation with your health care provider. But, he added, "For people without a high baseline risk, the risk of fracture is very small and the clear benefits to SGLT-2s outweigh that potential risk."

The findings were published online Jan. 1 in the Annals of Internal Medicine.

More information

Learn more about oral diabetes medications from the American Diabetes Association.